Inscription Capital LLC Sells 5,662 Shares of ICU Medical, Inc. $ICUI

Inscription Capital LLC decreased its position in ICU Medical, Inc. (NASDAQ:ICUI) by 67.7% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,703 shares of the medical instruments supplier’s stock after selling 5,662 shares during the quarter. Inscription Capital LLC’s holdings in ICU Medical were worth $386,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in ICU Medical by 3.4% in the fourth quarter. Vanguard Group Inc. now owns 2,714,746 shares of the medical instruments supplier’s stock valued at $387,313,000 after acquiring an additional 89,755 shares during the period. M&T Bank Corp lifted its holdings in ICU Medical by 163.1% in the fourth quarter. M&T Bank Corp now owns 6,218 shares of the medical instruments supplier’s stock valued at $978,000 after acquiring an additional 3,855 shares during the period. Optas LLC bought a new position in ICU Medical in the fourth quarter valued at about $334,000. Kirr Marbach & Co. LLC IN lifted its holdings in ICU Medical by 3.3% in the fourth quarter. Kirr Marbach & Co. LLC IN now owns 37,290 shares of the medical instruments supplier’s stock valued at $5,320,000 after acquiring an additional 1,197 shares during the period. Finally, State of Alaska Department of Revenue lifted its holdings in ICU Medical by 1.1% in the fourth quarter. State of Alaska Department of Revenue now owns 14,032 shares of the medical instruments supplier’s stock valued at $2,001,000 after acquiring an additional 149 shares during the period. Institutional investors own 96.10% of the company’s stock.

ICU Medical Stock Performance

Shares of ICUI opened at $115.45 on Thursday. The company has a quick ratio of 1.15, a current ratio of 2.39 and a debt-to-equity ratio of 0.60. The business has a 50-day simple moving average of $131.57 and a two-hundred day simple moving average of $138.12. The stock has a market cap of $2.89 billion, a price-to-earnings ratio of 5,775.39, a PEG ratio of 1.77 and a beta of 0.85. ICU Medical, Inc. has a 52 week low of $107.00 and a 52 week high of $160.29.

ICU Medical (NASDAQ:ICUI) last issued its quarterly earnings results on Thursday, February 19th. The medical instruments supplier reported $1.91 EPS for the quarter, topping analysts’ consensus estimates of $1.68 by $0.23. ICU Medical had a return on equity of 7.33% and a net margin of 0.03%.The business had revenue of $535.94 million during the quarter, compared to analysts’ expectations of $541.20 million. During the same quarter in the prior year, the business posted $2.11 earnings per share. The business’s quarterly revenue was down 14.1% on a year-over-year basis. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. On average, analysts expect that ICU Medical, Inc. will post 6.31 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have weighed in on ICUI. Wall Street Zen downgraded ICU Medical from a “buy” rating to a “hold” rating in a report on Saturday, April 18th. Piper Sandler reduced their price target on ICU Medical from $178.00 to $163.00 and set an “overweight” rating for the company in a research report on Friday, April 17th. Weiss Ratings restated a “sell (d-)” rating on shares of ICU Medical in a research report on Thursday, January 22nd. Finally, KeyCorp reduced their price target on ICU Medical from $180.00 to $164.00 and set an “overweight” rating for the company in a research report on Monday. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $169.00.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.